

15. (new) The polypeptide of claim 14 wherein said sequence is WXXWHF (SEQ ID NO:11); where each X is independently any amino acid selected from G, A, I, L, V, S, T, or R.

16. (new) The polypeptide of claim 15 wherein said sequence is WVRWHF (SEQ ID NO:2) or a fragment thereof capable of binding to an E2F DNA-binding site.

17. (new) The polypeptide WVRWHF (SEQ ID NO:2) or a variant thereof, which variant comprises from one to three amino acid substitutions, and which is capable of binding to an E2F DNA-binding site.

18. (new) The polypeptide of claim 14 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC50 of less than 100µM.

19. (new) The polypeptide of claim 16 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC50 of less than 100µM.

20. (new) A polypeptide which comprises a first portion which has the amino acid sequence of the polypeptide of claim 14 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally

contiguous to the first portion, said second portion comprising a membrane translocation sequence.

21. (new) A polypeptide which comprises a first portion which has the amino acid sequence of the polypeptide of claim 18 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

22. (new) A composition comprising the polypeptide of claim 14 in association with a carrier or diluent.

23. (new) A composition comprising the polypeptide of claim 14 in association with a carrier or diluent.

24. (new) A multiple antigen peptide of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is the peptide of claim 14, Lys is lysine and X is a terminal group.

25. (new) A multiple antigen peptide of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is the peptide of claim 16, Lys is lysine and X is a terminal group.